Glucagon-like peptide 2 (GLP-2) influences the functionality of gastrointestinal tract by participating in the feedback loop to the brain for the control of food intake. It also controls digestion and absorption, and has tropic effects post chemotherapy injury or surgical resection. This peptide is also responsible for epithelial cell proliferation of the small bowel. Studies in rats show that this peptide enhances the effects of the ileal-brake hormones, GLP-1 and peptide YY. It also negatively regulates gastrointestinal motility and secretion. Thus, it has potential as a therapeutic agent in short-bowel syndrome.